Learn More
OBJECTIVE To compare the safety and effectiveness of three methods of reversing coagulopathic effects of warfarin in patients with potentially life-threatening intracranial hemorrhage. METHODS A retrospective electronic medical record review of 63 patients with warfarin-related intracranial hemorrhage between 2007 and 2010 in an integrated health care(More)
Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs(More)
Infection, graft-versus-host disease (GVHD), and to a lesser extent sinusoidal obstructive syndrome (SOS) represent the major causes of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). During the last decade, progress in prevention and treatment of these complications led to improvement in the(More)
BACKGROUND The modified Rankin Scale (mRS) is a 6-level outcome scale used to assess level of function in neurological disease. OBJECTIVE We examined the interobserver reliability and intraobserver reliability of the mRS-9Q, a 9-question "yes/no" survey that measures the mRS score in neurosurgical and neurological patients. METHODS The mRS-9Q was(More)
BACKGROUND To date, no ischemic stroke outcome prediction scores have been validated for use in the setting of both endovascular and non-endovascular stroke treatments. The Totaled Health Risks in Vascular Events (THRIVE) score has been previously validated in patients undergoing endovascular stroke treatment, and we hypothesized that it would perform(More)
Citation: el-amm et al. erratum for " Metastatic Castration-Resistant Prostate Cancer: Critical Review of enzalutamide ". CoPYRight: © the authors, publisher and licensee libertas academica limited. this is an open-access article distributed under the terms of the Creative Commons CC-By-nC 3.0 license.
The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. This review will provide a synopsis of the(More)
A total of 230 children undergoing closed reduction and percutaneous pinning of supracondylar humerus fractures were analyzed retrospectively. Severe pain (score ≥ 7/10) was reported in 10% of general anesthesia-only patients in the postanesthesia care unit and in 28% of the 130 admitted patients. The 36 patients who received ultrasound-guided regional(More)
Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) postdocetaxel. Preclinical studies have demonstrated impressive affinity to the AR compared(More)
OBJECTIVES Our objectives were to confirm the activity of O-MAX chemotherapy in adenocarcinoma of the stomach and esophagus, particularly the high rate of complete remission (CR) and the relation of subclinical hemolysis to CR. PATIENTS AND METHODS Twenty-five patients with metastatic esophagogastric adenocarcinoma were treated with O-MAX. Two developed(More)